VERVE-102 gene therapy shows 62% LDL reduction in Phase 1 — potential one-time treatment
Key Questions
What LDL reduction did VERVE-102 achieve in early trials?
The single-dose base editor reduced LDL by 62% in HeFH patients, with effects sustained for 18 months. No serious safety signals were observed.
What is the potential impact of VERVE-102 on patient adherence?
As a one-time treatment, it could transform adherence for high-risk patients. Phase 2 trials are planned to expand testing to broader populations.
Who developed and now owns VERVE-102?
Eli Lilly acquired the PCSK9 base editor from Verve Therapeutics. Early data have generated excitement for its role in cholesterol management.
Eli Lilly's single-shot base editor (acquired from Verve) reduced LDL by 62% in HeFH patients, sustained 18 months with no serious safety signals. Phase 2 planned. Could transform adherence for high-risk patients if expanded to broader populations.
Sources (2)
Updated May 26, 2026